- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02656225
Effect of Ejiao Compound in the Treatment of Postpartum Anemia of Qi-blood Deficiency Syndrome
Effect of Ejiao Compound in the Treatment of Postpartum Anemia of Qi-blood Deficiency Syndrome: Study Protocol of a Randomized Controlled Trial
The prevalence of postpartum anemia is a great threat for maternal and infant health without timely and effective treatment. Oral iron therapy has been used for centuries as a treatment of anemia, however, it is noteworthy that treatment with oral iron might have a limited, and even a harmful role in some clinical scenarios. Ejiao compound is composed with donkey-hide glue, Ginseng, Codonopsis pilosula, prepared rhizome of rehmannia, and crab apple, which has been widely used in the treatment of various types of anemia in China for decades and might be a potentially effective therapy for postpartum anemia. Recently, studies involving animal subjects have helped shed light on its mechanism of action.
In this study, the investigators aimed to conduct a randomized controlled trial to assess the efficacy and safety of Ejiao compound comparing with oral iron in the treatment of mild postpartum anemia with or without iron deficiency.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
- Study type: This is a randomized, parallel controlled and single blind study. The sample ratio of the experimental group and the control group will be 1:1.
- Study Setting and Recruitment: All participants experience vaginal delivery and are diagnosed with mild postpartum anemia. They will be recruited from the obstetric inpatient department in two hospitals: the first affiliated hospital of Guangzhou University of Traditional Chinese Medicine, and Maternal and Child Health Hospital of Panyu District in Guangzhou City. All assessments and interventions will occur at hospitals.
- Randomization, blinded method, and allocation concealment: Patients meeting the criteria were randomized into experimental group or control group, according to a computer-generated list. The patients in experimental group will receive the treatment of Ejiao compound while the patients in control group will be treated by Polysaccharide iron complex. The study physicians will receive a sealed decoding envelope per treatment, they will not know the identity of the participants, will not handle the study products, will not know the assigned treatment, and will not share their own examination results. After receiving the evaluation by the study physicians and finishing the investigation form, the patient will take her own sealed decoding envelope and go to the pharmacy of the clinical trial center to receive her medication. The staff of the pharmacy of the clinical trial center is responsible for the distribution and return of experimental drugs to patients. All envelopes, sealed or unsealed, will be returned to the investigators at the end of the study. Patients would be required to return boxes whether they are used and unused at each visit and compliance will be assessed by counting the bottles and capsules.
- Sample size calculation: It was reported that treatment with oral iron for anemia in postpartum women increase the Hb concentration by 49.3% by day 40. Combined with etiological treatment, Ejiao compound used to treat anemia in non pregnant population for three months, the Hb concentration increased by 66.9%. Basing on the results of literatures mentioned above, the investigators suppose that the difference of Hb concentration between patients only receiving the Ejiao compound for 4 weeks and patients only receiving oral iron for 4 weeks would be 25.0%. The α-value is set at 0.05 and the test power is 0.90. The final sample size should be 68 in each group. With an anticipated dropout rate of 20% during the follow-up, the initial sample size for each group should be 85, and 170 in total for two groups.
- Statistical analysis: The statisticians will be blinded to the allocation of the participants. Statistics Package for Social Science (SPSS)19.0 statistical software packages will be used to analyze the data. The intention-to-treat population will include all randomized patients who receive the assigned treatment at least once, and who have an evaluation of outcomes. The measurement data will be analyzed by using t-test or the rank sum test, and the numeration data will be analyzed by using chi-square test or Fisher's exact test. P<0.05 indicates statistical significance.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510405
- Recruiting
- the First Affiliated Hospital, Guangzhou University of Chinese Medicine
-
Contact:
- Yanfang Li, PhD
- Phone Number: +86 13928777126
- Email: gzyanfangli@hotmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Women aged 18 years to 45 years with mild postpartum anemia (Hb <10 g/dl and ≥7 g/dl at 24-48 hours postpartum);
- Absence of antepartum anemia, which is defined as Hb≥11.0 g/dL within 48 hours before delivery;
- Singleton pregnancy;
- Type of syndrome in Traditional Chinese Medicine is "Qi-blood deficiency".
- Patients having not received blood transfusion or any forms of anti-anemia treatment in Western medicine or TCM in the last 12 weeks;
- Informed consent obtained.
Exclusion Criteria:
- Type of syndrome in TCM is NOT "Qi-blood deficiency";
- Antepartum anemia;
- Twin or multiple pregnancies;
- A history of haematological disease (e.g. sickle cell anemia or thalassemias);
- A history of undigestive disease (e.g. gastric ulcer, gastritis) or inflammatory bowel disease;
- A history of cardiovascular diseases, renal or liver disease, asthma, thromboembolism, HIV infection, tuberculosis, cancer and seizures;
- Patients having received blood transfusion or any forms of anti-anemia treatment in Western medicine or TCM in the last 12 weeks;
- Alcohol or drug abuse;
- Patients with mental illness or poor compliance to medical treatment;
- Participation in another clinical trial within the previous three months;
- No informed consent obtained.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ejiao compound
The participants in experimental group receive Ejiao compound (20ml, twice daily) orally for 4 weeks.
|
20ml,twice daily, orally after breakfast Duration:4 weeks
Other Names:
|
Active Comparator: Niferex
The participants in control group receive Polysaccharide Iron Complex(Niferex)(150mg per tablet, once daily) orally after breakfast over 4 weeks.
|
one tablet,once daily, orally after breakfast Duration:4 weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Hemoglobin(Hb)
Time Frame: before and after treatment
|
before and after treatment
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Serum ferritin
Time Frame: before and after treatment
|
before and after treatment
|
Life quality assessment: a Health Assessment Questionnaire(The Short Form-36 Health Survey, SF-36)
Time Frame: before and after treatment
|
before and after treatment
|
Traditional Chinese Medicine symptom score:a self-made scale for Qi-blood Deficiency Syndrome
Time Frame: before and after treatment
|
before and after treatment
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse reactions or events: renal function
Time Frame: before and after treatment
|
serum creatinine and urea nitrogen
|
before and after treatment
|
Adverse reactions or events: liver function
Time Frame: before and after treatment
|
aspartate aminotransferase(AST), alanine aminotransferase (ALT)
|
before and after treatment
|
Collaborators and Investigators
Investigators
- Study Chair: yanfang Li, PhD, the First Affiliated Hospital, Guangzhou University of Chinese Medicine
Publications and helpful links
General Publications
- Milman N. Postpartum anemia I: definition, prevalence, causes, and consequences. Ann Hematol. 2011 Nov;90(11):1247-53. doi: 10.1007/s00277-011-1279-z. Epub 2011 Jun 28.
- Dodd J, Dare MR, Middleton P. Treatment for women with postpartum iron deficiency anaemia. Cochrane Database Syst Rev. 2004 Oct 18;2004(4):CD004222. doi: 10.1002/14651858.CD004222.pub2.
- Bhandal N, Russell R. Intravenous versus oral iron therapy for postpartum anaemia. BJOG. 2006 Nov;113(11):1248-52. doi: 10.1111/j.1471-0528.2006.01062.x. Epub 2006 Sep 27.
- Ramakers C, van der Woude DA, Verzijl JM, Pijnenborg JM, van Wijk EM. An added value for the hemoglobin content in reticulocytes (CHr) and the mean corpuscular volume (MCV) in the diagnosis of iron deficiency in postpartum anemic women. Int J Lab Hematol. 2012 Oct;34(5):510-6. doi: 10.1111/j.1751-553X.2012.01423.x. Epub 2012 May 1.
- Breymann C, Honegger C, Holzgreve W, Surbek D. Diagnosis and treatment of iron-deficiency anaemia during pregnancy and postpartum. Arch Gynecol Obstet. 2010 Nov;282(5):577-80. doi: 10.1007/s00404-010-1532-z. Epub 2010 Jun 25.
- Milman N. Postpartum anemia II: prevention and treatment. Ann Hematol. 2012 Feb;91(2):143-54. doi: 10.1007/s00277-011-1381-2. Epub 2011 Dec 9.
- Bergmann RL, Richter R, Bergmann KE, Dudenhausen JW. Prevalence and risk factors for early postpartum anemia. Eur J Obstet Gynecol Reprod Biol. 2010 Jun;150(2):126-31. doi: 10.1016/j.ejogrb.2010.02.030. Epub 2010 Mar 29.
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PA-1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Postpartum Anemia
-
DongE E Jiao Coporation LimitedNot yet recruiting
-
HaEmek Medical Center, IsraelCompleted
-
American Regent, Inc.CompletedPostpartum AnemiaUnited States
-
HaEmek Medical Center, IsraelCompleted
-
Dow University of Health SciencesCompleted
-
University of PennsylvaniaCompletedPostpartum Anemia NosUnited States
-
NICHD Global Network for Women's and Children's...Boston University; University of Colorado, Denver; University of Alabama at Birmingham and other collaboratorsRecruitingPostpartum AnemiaZambia, Congo, The Democratic Republic of the, India, Bangladesh, Pakistan, Guatemala, Kenya
-
University Medical Centre LjubljanaCompletedIron-deficiency | Postpartum Anemia NosSlovenia
-
Unity Health TorontoCompleted
-
Norwegian University of Science and TechnologySt. Olavs Hospital; Sykehuset Innlandet HF; Sykehuset Buskerud HFTerminatedAnemia, Iron-Deficiency | Depression, Postpartum | Puerperal DisordersNorway
Clinical Trials on Ejiao compound
-
Royal Marsden NHS Foundation TrustMerck KGaA, Darmstadt, GermanyActive, not recruitingSoft-tissue SarcomaUnited Kingdom
-
Arafat TfayliMerck KGaA, Darmstadt, Germany; Phoenix Clinical ResearchUnknownNon-Small Cell Lung Cancer StageLebanon, Jordan
-
Chinese PLA General HospitalCompletedBreast Neoplasms | Lung NeoplasmsChina
-
Neuromed IRCCSCompleted
-
Imperial College LondonBritish Heart FoundationRecruitingDilated CardiomyopathyUnited Kingdom
-
CeleCor TherapeuticsDiagram B.V.; ST. Antonius hospital NieuwegeinCompletedMyocardial Infarction | Heart Diseases | Vascular Diseases | Coronary Disease | STEMI - ST Elevation Myocardial InfarctionNetherlands
-
Technological Centre of Nutrition and Health, SpainUniversity Rovira i Virgili; Hospital Universitari Sant Joan de Reus; Fundació...UnknownBlood Pressure | Cardiovascular Risk FactorsSpain
-
Celon Pharma SANational Center for Research and Development, PolandCompletedHealthy VolunteersPoland
-
Örebro University, SwedenRecruitingMicroscopic ColitisSweden
-
The Netherlands Cancer InstituteGlaxoSmithKlineCompletedSarcoma,Soft TissueNetherlands